1/14
09:02 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) was given a new $39.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a "neutral" rating on the stock.
Low
Report
TG Therapeutics (NASDAQ:TGTX) was given a new $39.00 price target on by analysts at The Goldman Sachs Group, Inc.. They now have a "neutral" rating on the stock.
1/14
06:02 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "overweight" rating reaffirmed by analysts at Cantor Fitzgerald.
1/14
03:53 am
tgtx
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones [Yahoo! Finance]
Low
Report
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones [Yahoo! Finance]
1/13
04:25 pm
tgtx
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
Medium
Report
TG Therapeutics Provides Preliminary Fourth Quarter and Full Year 2025 Net Product Revenue and 2026 Revenue Guidance and Anticipated Development Milestones
1/7
07:30 am
tgtx
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
Medium
Report
TG Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference
12/30
11:11 am
tgtx
TG Therapeutics: What Wall Street Isn't Telling You [Seeking Alpha]
Low
Report
TG Therapeutics: What Wall Street Isn't Telling You [Seeking Alpha]
12/28
04:01 pm
tgtx
Investing in TG Therapeutics (NASDAQ:TGTX) three years ago would have delivered you a 160% gain [Yahoo! Finance]
Low
Report
Investing in TG Therapeutics (NASDAQ:TGTX) three years ago would have delivered you a 160% gain [Yahoo! Finance]
12/23
04:13 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
12/14
01:27 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at
Wall Street Ze
Low
Report
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at
Wall Street Ze
12/6
01:36 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at
Wall Street
Low
Report
TG Therapeutics (NASDAQ:TGTX) was downgraded by analysts at
Wall Street
12/2
03:46 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/28
07:30 am
tgtx
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
Low
Report
TG Therapeutics to Participate in the 8th Annual Evercore Healthcare Conference
11/26
02:20 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c+)" rating reaffirmed by analysts at
Weiss Ratings.
11/19
08:30 am
tgtx
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
Medium
Report
TG Therapeutics Makes 2025 Deloitte Technology Fast 500™ List of America’s Fastest-Growing Companies
11/18
02:25 am
tgtx
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing [Seeking Alpha]
Low
Report
TG Therapeutics: Positives From Q3'25 Earnings, But Competitors Progressing [Seeking Alpha]
11/10
04:00 pm
tgtx
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
Low
Report
TG Therapeutics to Participate in the TD Cowen Immunology & Inflammation Summit
11/5
07:32 am
tgtx
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
Low
Report
TG Therapeutics (NASDAQ:TGTX) was upgraded by analysts at B. Riley to a "strong-buy" rating.
11/3
11:03 am
tgtx
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an "overweight" rating on the stock.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its price target raised by analysts at JPMorgan Chase & Co. from $46.00 to $49.00. They now have an "overweight" rating on the stock.
11/3
07:00 am
tgtx
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
Medium
Report
TG Therapeutics Reports Third Quarter 2025 Financial Results and Raises BRIUMVI Revenue Guidance
10/31
07:30 am
tgtx
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
Low
Report
TG Therapeutics to Host Conference Call on Third Quarter 2025 Financial Results and Business Update
10/28
07:30 am
tgtx
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
Low
Report
TG Therapeutics Completes Enrollment in the Phase 3 ENHANCE Trial Evaluating its New Simplified Dosing Schedule for BRIUMVI
10/25
12:13 pm
tgtx
TG Therapeutics (NASDAQ:TGTX) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
TG Therapeutics (NASDAQ:TGTX) had its "hold (c-)" rating reaffirmed by analysts at
Weiss Ratings.